latanoprost ocular implant (PA5108) / PolyActiva - LARVOL DELTA

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma (clinicaltrials.gov) - P1 | N=37 | Completed | Sponsor: PolyActiva Pty Ltd | Active, not recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ May 2025

Trial completion • Trial completion date • Glaucoma • Ophthalmology

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: PolyActiva Pty Ltd | Trial completion date: Feb 2025 ➔ Oct 2025 | Trial primary completion date: Sep 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: PolyActiva Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: PolyActiva Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: PolyActiva Pty Ltd

New P2 trial • Cardiovascular • Glaucoma • Ophthalmology

Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: PolyActiva Pty Ltd

New P1 trial • Cardiovascular • Glaucoma • Ophthalmology

Polymeric Implants with Sustained-Release of Latanoprost or Latanoprost Free Acid to Lower Intraocular Pressure: The Importance of Anatomic Location (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Glaucoma • Ophthalmology

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: PolyActiva Pty Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2023 ➔ Feb 2025 | Trial primary completion date: Aug 2023 ➔ Sep 2024

Enrollment closed • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension. (clinicaltrials.gov) - P1 | N=1 | Completed | Sponsor: PolyActiva Pty Ltd | Recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension. (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: PolyActiva Pty Ltd

New P1 trial • Glaucoma • Ophthalmology

Phase I study of a Latanoprost Ocular Implant for treatment of Open Angle Glaucoma or Ocular Hypertension. (ANZCTR) - P1 | N=6 | Recruiting | Sponsor: PolyActiva Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Phase I study of a Latanoprost Ocular Implant for treatment of Open Angle Glaucoma or Ocular Hypertension. (ANZCTR) - P1 | N=6 | Not yet recruiting | Sponsor: PolyActiva Pty Ltd

New P1 trial • Glaucoma • Ophthalmology

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: PolyActiva Pty Ltd; N=30 ➔ 40; Trial completion date: Dec 2021 ➔ Aug 2023; Trial primary completion date: Nov 2021 ➔ Aug 2023

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: PolyActiva Pty Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Glaucoma • Ophthalmology

Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma (clinicaltrials.gov) - P1; N=8; Completed; Sponsor: PolyActiva Pty Ltd; Active, not recruiting ➔ Completed

Clinical • Trial completion • Glaucoma • Ophthalmology

Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma (clinicaltrials.gov) - P1; N=7; Active, not recruiting; Sponsor: PolyActiva Pty Ltd; Recruiting ➔ Active, not recruiting; Trial completion date: Sep 2019 ➔ Sep 2020; Trial primary completion date: May 2019 ➔ May 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: PolyActiva Pty Ltd; Initiation date: Nov 2019 ➔ Feb 2020

Clinical • Trial initiation date